Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients
Clinical trial NCT02437279 · UNKNOWN
Trial details
- NCT number
- NCT02437279
- Sponsor
- The Netherlands Cancer Institute
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-24
- Primary completion
- 2018-06-28
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.